EpiEndo Pharmaceuticals: Funding, Investors & Team (Oct 2026)
EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity as a causal pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human skin and lung tissue, as well as the intestinal tract and genitalia. Compromised integrity of this barrier is implicated in the progression and non-resolution of inflammation. EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic respiratory diseases and other significant unmet medical needs. EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, disease modifying, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for COPD and other inflammatory airway diseases.
EpiEndo Pharmaceuticals has raised $23.4M across 1 funding round on record, the most recent a Series A of $23.4M announced in Aug 2021.
That round is above the $5.0M median round size for Health Care companies tracked on FundedIQ over the last two years.
EpiEndo Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Aug 2021.
EpiEndo Pharmaceuticals Funding Rounds
EpiEndo Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
EpiEndo Pharmaceuticals Funding Compared to Other Health Care Startups
EpiEndo Pharmaceuticals' latest round of $23.4M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like EpiEndo Pharmaceuticals in Health Care and Reykjavík
Companies Similar to EpiEndo Pharmaceuticals
Sidekick is a patient-centric digital care platform that is scalable across a wide range of chronic…
PLAIO is an online software as a service tool designed for generic pharmaceutical companies to streamline…
Kerecis creates licensed fish-skin items to mend the human body. Since no sickness move risk exists between…
PLAIO is a web-based SaaS platform intended to help generic pharmaceutical companies to digitize their…
Treso operates as a financial software provider that develops an integrated financial operating system…
MakeO is a company that creates a full range of oral and skin care solutions, allowing individuals to achieve…
Optain produces medical tools and technology with the aim of providing healthcare access to everyone,…
Yazen is a digital healthcare provider that offers tailored weight loss programs, combining medical…
We are pioneering the use of semiconductor technology for next-generation neural implants. Our mission is to…
Using technology and the best professionals, Wally, a membership-based dental care service, offers proactive,…
PreciseDx is a unique Cancer Risk Stratification company that offers personalized risk information by…
General Medicine provides a convenient and straightforward way to access top-quality healthcare services with…
EpiEndo Pharmaceuticals Funding FAQs
What does EpiEndo Pharmaceuticals do?
EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity as a causal pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human skin and lung tissue, as well as the intestinal tract and genitalia. Compromised integrity of this barrier is implicated in the progression and non-resolution of inflammation. EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic respiratory diseases and other significant unmet medical needs. EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, disease modifying, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for COPD and other inflammatory airway diseases.
How much funding has EpiEndo Pharmaceuticals raised?
EpiEndo Pharmaceuticals has raised $23.4M across 1 round on record. The most recent is a Series A of $23.4M announced in Aug 2021.
When did EpiEndo Pharmaceuticals last raise funding?
EpiEndo Pharmaceuticals' most recent funding round on record is a Series A of $23.4M, announced in Aug 2021.
Who is the CEO of EpiEndo Pharmaceuticals?
Maria Bech is listed as CEO at EpiEndo Pharmaceuticals.
Where is EpiEndo Pharmaceuticals headquartered?
EpiEndo Pharmaceuticals is based in Reykjavík, Gullbringusysla, Iceland.
How many employees does EpiEndo Pharmaceuticals have?
EpiEndo Pharmaceuticals is in the 11-50 employee band.
How does EpiEndo Pharmaceuticals' funding compare to other Health Care startups?
EpiEndo Pharmaceuticals' latest round of $23.4M is above the $5.0M median round size for Health Care companies on FundedIQ across 3,660 tracked companies over the last two years.
About FundedIQ's EpiEndo Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for EpiEndo Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.